Reviewing Menlo Therapeutics Inc. (MNLO)’s and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE)’s results

Both Menlo Therapeutics Inc. (NASDAQ:MNLO) and Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Menlo Therapeutics Inc. 10.64M 17.07 51.45M -2.40 0.00
Zynerba Pharmaceuticals Inc. N/A 0.00 40.24M -2.88 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 hightlights the return on equity, net margins and return on assets of the two companies.

Net Margins Return on Equity Return on Assets
Menlo Therapeutics Inc. -483.55% -37.2% -27%
Zynerba Pharmaceuticals Inc. 0.00% -74.8% -63.3%


Menlo Therapeutics Inc.’s Current Ratio is 19.2 while its Quick Ratio is 19.2. On the competitive side is, Zynerba Pharmaceuticals Inc. which has a 8 Current Ratio and a 8 Quick Ratio. Menlo Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Zynerba Pharmaceuticals Inc.

Institutional & Insider Ownership

The shares of both Menlo Therapeutics Inc. and Zynerba Pharmaceuticals Inc. are owned by institutional investors at 79.1% and 17.3% respectively. 19.12% are Menlo Therapeutics Inc.’s share held by insiders. Competitively, insiders own roughly 1.1% of Zynerba Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Menlo Therapeutics Inc. 5.07% 58.69% 38.27% 5.6% -73.82% 106.07%
Zynerba Pharmaceuticals Inc. 0.6% -3.24% 3.05% -36.62% -47.62% 70.71%

For the past year Menlo Therapeutics Inc. has stronger performance than Zynerba Pharmaceuticals Inc.


Menlo Therapeutics Inc. beats Zynerba Pharmaceuticals Inc. on 7 of the 9 factors.

Menlo Therapeutics Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of serlopitant for the treatment of pruritus associated with dermatologic conditions in the United States. The company has completed Phase II clinical trials in pruritus associated with prurigo nodularis. It is also developing products that are in Phase II clinical trials to treat pruritus associated with psoriasis, atopic dermatitis, and refractory chronic cough. The company was formerly known as Tigercat Pharma, Inc. and changed its name to Menlo Therapeutics Inc. in May 2016. Menlo Therapeutics Inc. was founded in 2011 and is headquartered in Redwood City, California.

Zynerba Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates include ZYN002, which is in Phase II clinical trial for adult patients with refractory epileptic focal seizures and osteoarthritis, as well as pediatric patients with fragile X syndrome; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.